A market research release says about 30 obesity drugs are in late-stage trials, with Lilly, Novo, Viking, Pfizer and dozens of Chinese firms in the race.
Recap by typeshit. Full story at Yahoo Finance.
Dr Alo, a cardiologist, says he is following the cardiovascular data on these drugs closely and that it is shifting how heart disease is treated.
50:28
DOWNSIZED looks at why appetite and food noise can creep back late in the weekly cycle, and what that may say about whether a GLP-1 is still working.
Avi Roy points to trial data on drugs like Ozempic, including a 16-week study of 73 people where milkshake ratings barely changed despite reduced appetite.
Research presented at the anesthesiology meeting linked GLP-1 use with lower odds of heart attack and other heart problems. It shows an association, not proof of cause.
Suppliers get around medicines rules by labelling the products as not for human consumption, since the peptides aren't licensed as medicines.
Weight loss and diabetes drugs bring in more than 60% of Lilly's revenue, and Forbes looks at where the CEO is putting billions next.
Loading…